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Events in Adalimumab Clinical Trials Across Nine Different 
Diseases
Dirk Elewaut,1  Jürgen Braun,2 Jaclyn K. Anderson,3 Dilek Arikan,3 Su Chen,3 Maja Hojnik,4  
Ann-Sophie De Craemer,1 and Jeffrey R. Curtis5
Objective. Adalimumab is approved for treatment of Crohn’s disease and ulcerative colitis. Thus, we postulated 
that exacerbation or new-onset of inflammatory bowel disease (IBD) would be rare events in patients treated with 
adalimumab for non-IBD indications. The objective was to evaluate the incidence of IBD adverse events (AEs) across 
adalimumab trials.
Methods. IBD AE rates in 75 adalimumab clinical trials in rheumatoid arthritis, polyarticular juvenile idiopathic 
arthritis, pediatric enthesitis-related arthritis, uveitis, hidradenitis suppurativa, adult and pediatric psoriasis, psoriatic 
arthritis, nonpsoriatic arthritis peripheral spondyloarthritis (SpA), axial SpA, including nonradiographic axial SpA, 
and ankylosing spondylitis, were analyzed. Search terms for IBD AEs (new onset or worsening/flare) included IBD, 
ulcerative colitis, Crohn’s disease, and ulcerative proctitis.
Results. This analysis included 24,114 patients, representing 36,508 patient-years of adalimumab exposure. The 
overall rate of IBD AEs in adalimumab-treated patients was 0.1 (95% confidence interval [95% CI] 0.1–0.2)/100 
patient-years (41 events), ranging from no events (psoriatic arthritis, uveitis, and pediatric trials) to 0.8 (95% CI 
0.2–2.2)/100 patient-years in peripheral SpA. The rate of IBD in axial SpA was 0.6 (95% CI 0.4–1.0)/100 patient-years. 
During placebo-controlled trials, the overall IBD rate was 0.1 (95% CI 0.0–0.3)/100 patient-years for adalimumab 
groups (3 events in 6,781 patients; 2,752 patient-years of exposure) and 0.1 (95% CI 0.0–0.4)/100 patient-years for 
placebo groups (1 event in 3,493 patients; 1,246 patient-years of exposure). IBD rates in axial SpA were 0.5 (95% CI 
0.1–1.4)/100 patient-years for adalimumab and 0.6 (95% CI 0.0–3.1)/100 patient-years for placebo.
Conclusion. The rates of IBD AEs in adalimumab clinical trials were generally low across the evaluated diseases, 
including axial SpA; all events occurred in adult patients.
INTRODUCTION
Tumor necrosis factor (TNF) and interleukin-17 (IL-17), among 
other cytokines, play a role in inflammatory bowel disease (IBD) and 
other immune-mediated inflammatory diseases (IMIDs) (1). Previous 
studies have shown that TNF contributes to intestinal inflammation 
and is elevated in the serum and intestinal cells of patients with IBD 
(2). Monoclonal TNF inhibitors (i.e., adalimumab, infliximab, certo-
lizumab, and golimumab) are effective for the treatment of IBD, 
while etanercept, a TNF receptor fusion protein, is not (3).
Similarly to TNF, IL-17 levels are increased in patients with IBD 
and contribute to intestinal inflammation by stimulating various cell 
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types to produce proinflammatory mediators (4). However, avail-
able data indicate that IL-17 inhibition (e.g., with a monoclonal 
antibody blocking IL-17A [secukinumab]) is both ineffective and 
may worsen IBD (5,6).
Adalimumab is approved for the treatment of 15 indications 
worldwide, including adult and pediatric Crohn’s disease and adult 
ulcerative colitis. Therefore, exacerbations of existing or new- onset 
IBD may be rare events in patients treated with adalimumab for 
non-IBD indications. The overall rate of new onset or worsening of 
IBD across adalimumab clinical trials is unknown and is of particu-
lar interest in patients with axial spondyloarthritis (SpA) who have a 
high prevalence of both overt IBD and subclinical gut inflammation 
(7,8). The objective of this analysis was to report the incidence of 
IBD adverse events (AEs) in adalimumab clinical trials across indi-
cations, with a specific focus on IBD occurrence in patients with 
axial SpA, including patients with ankylosing spondylitis (AS) and 
nonradiographic axial SpA.
PATIENTS AND METHODS
Patients. This post hoc analysis assessed the rates of IBD 
AEs in patients with rheumatoid arthritis (RA), polyarticular juvenile 
idiopathic arthritis (JIA), pediatric enthesitis-related arthritis (ERA), 
uveitis (noninfectious intermediate, posterior, or pan-uveitis), 
hidradenitis suppurativa, adult and pediatric psoriasis (including 
nail psoriasis), psoriatic arthritis (PsA), non-PsA peripheral SpA, 
nonradiographic axial SpA, and AS, who participated in phase 
II through phase IV of interventional, adalimumab clinical trials 
(Table 1); patient data from registry, noninterventional, and real-
world studies were not included in the analysis. Adalimumab trials 
conducted specifically in patients with Crohn’s disease, ulcerative 
colitis, and intestinal Behçet’s disease were excluded from this 
analysis. Gastrointestinal-related exclusion criteria varied by trial, 
ranging from a specific exclusion for active or unstable IBD (10 
RA, 6 psoriasis, 2 nonradiographic axial SpA, 1 peripheral SpA, 
and 1 PsA trials) to less specific exclusions for unstable or poorly 
controlled medical conditions or underlying conditions considered 
by the investigator as an unacceptable risk for trial participation. 
Thus, none of the trials included in this analysis excluded patients 
with a history of IBD. The presence of prevalent IBD at baseline was 
not systematically characterized for the entire study population in 
any of the trials. (For information on requesting data from AbbVie- 
sponsored studies, visit: https://www.abbvie.com/our-scien ce/ 
clini cal-trial s/clini cal-trial s-data-and-infor matio n-shari ng/ 
data-and-infor matio n-shari ng-with-quali fied-resea rchers.html).
Assessment of IBD. Data on IBD (new onset, worsening/
flare) were collected as AEs reported throughout the duration of 
the trials and through 70 days (5 half-lives) after the last dose 
of adalimumab. The search criteria for IBD events included the 
following standardized Medical Dictionary for Regulatory Activ-
ities preferred terms (either new onset or worsening/flare): IBD, 
ulcerative colitis, Crohn’s disease, IBD not otherwise specified, 
and ulcerative proctitis. Gastrointestinal perforation was outside 
the scope of the search criteria. The automated search did not 
distinguish between new-onset IBD and flare of preexisting IBD. 
A manual assessment to distinguish new-onset IBD and worsen-
ing of preexisting disease was performed for the events occurring 
in patients with axial SpA (AS and nonradiographic axial SpA).
Statistical analysis. IBD AEs (combined for new onset and 
flare) were reported as the number of patients with an IBD event, 
the total number of events (i.e., each event was recorded sepa-
rately for patients with >1 event), and the number of events when 
censored after the first event. Rates of IBD events were calculated 
as events per 100 patient-years; 95% confidence intervals (95% 
CIs) were based on exact confidence limits from a Poisson distri-
bution. IBD event rates were determined for all patients treated 
SIGNIFICANCE & INNOVATIONS
• The results of this analysis of 75 adalimumab clinical 
trials in adult and pediatric patients demonstrated 
that the rates of inflammatory bowel disease (IBD) 
adverse events were generally low across non-IBD 
diseases, with all events occurring in adult patients.
• In patients with axial spondyloarthritis who have an 
increased risk of IBD, the rates of IBD events were 
comparable between adalimumab- and placebo- 
treated patients.
• Based on these data, adalimumab is a reasonable 
therapeutic option for patients who are eligible for 
a biologic therapy and who are at risk for develop-
ment or worsening of IBD.
Table 1. Number of clinical trials and patient exposure per diseases 
included in the analysis*
Disease Trials, no. Patients, no. (PY)
All adalimumab trials 75 24,114 (36,508)
RA 35 15,152 (24,813)
Psoriasis, adult 17 3,703 (5,409)
All SpA† 12 3,891 (4,363)
AS 5 2,026 (2,120)
Nonradiographic axial SpA 2 863 (855)
PsA 4 837 (998)
Peripheral SpA 1 165 (391)
Hidradenitis suppurativa 4 733 (836)
JIA‡ 4 274 (797)
Uveitis 2 250 (167)
Psoriasis, pediatric 1 111 (122)
* Excludes adalimumab trials in Crohn’s disease, ulcerative colitis, 
and Behçet’s disease. AS = ankylosing spondylitis; JIA = juvenile 
idiopathic arthritis; PsA = psoriatic arthritis; PY = patient-years; SpA = 
spondyloarthritis; RA = rheumatoid arthritis. 
† Includes patients with PsA, peripheral SpA, nonradiographic axial 
SpA, and AS from interventional adalimumab trials. 
‡ Includes patients with polyarticular JIA and pediatric enthesitis-
related arthritis from interventional adalimumab trials. 
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with adalimumab during the studies (any adalimumab population, 
patients who received at least 1 dose of adalimumab), as well as 
separately for placebo- and adalimumab-treated patients during 
the placebo-controlled periods.
To improve comparability between the studies with other-
wise varying durations of follow-up, and given the potential for a 
time-varying hazard of IBD events, the event rate of IBD events 
over the first 1-year period in each trial was also calculated 
Figure 1. Patients treated with adalimumab in clinical trials, including long-term extensions. Excludes patient data from registry, noninterventional, 
real-world studies and from adalimumab trials in Crohn’s disease, ulcerative colitis, and Behçet’s disease. A, Rates of all inflammatory bowel 
disease (IBD) events per 100 patient-years (PY). B, Rates of first IBD events only per 100 patient-years (with patients censored after first 
event). 95% CI = 95% confidence interval; * = includes patients with psoriatic arthritis (PsA), non-PsA peripheral spondyloarthritis (pSpA), 
nonradiographic axial SpA (nr-axSpA), and ankylosing spondylitis (AS) from interventional adalimumab trials; † = includes patients with 
nonradiographic axial SpA and AS from interventional adalimumab trials; ‡ = includes patients with polyarticular juvenile idiopathic arthritis (JIA) 
and pediatric enthesitis-related arthritis from interventional adalimumab trials; HS = hidradenitis suppurativa; RA = rheumatoid arthritis.
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(patients initially receiving placebo were included at the time of 
first adalimumab dose up to year 1).
RESULTS
This analysis included 75 interventional adalimumab clini-
cal trials in 24,114 patients, representing 36,508 patient-years 
of adalimumab exposure (Table 1). The largest exposure was in 
patients with RA (15,152 patients; 24,813 patient-years). A total 
of 2,026 patients from AS studies (2,120 patient-years) and 863 
patients from nonradiographic axial SpA studies (855 patient-
years) were included.
Overall, 41 IBD events (rate of 0.1/100 patient-years) were 
reported across all trials (Figure 1A). The rates of IBD events varied 
across diseases, ranging from no IBD events (PsA, uveitis, and 
pediatric indications) to 0.8/100 patient-years (peripheral SpA) 
(Figure 1A). Thirty-one patients experienced an IBD event, cor-
responding to an overall IBD rate of 0.1/100 patient-years when 
patients were censored after the first event (Figure 1B).
Across the axial SpA trials, corresponding to 2,889 patients 
and 2,975 patient-years of exposure, the rate of IBD in adali-
mumab-treated patients was 0.6/100 patient-years (18 events), 
14 events (0.7/100 patient-years) in 12 patients with AS, and 4 
events (0.5/100 patient-years) in 3 patients with nonradiographic 
axial SpA (Figure 1A). In patients with AS, the 14 IBD events con-
sisted of 7 new-onset events and 7 flares, and in patients with 
nonradiographic axial SpA, the 4 IBD events consisted of 4 flares. 
Among the 15 patients with an IBD event, 5 patients with AS and 
all 3 patients with nonradiographic axial SpA had a prior history 
of IBD; none of these 15 patients prematurely discontinued from 
the trial. A total of 34 patients with AS and 30 patients with nonra-
diographic axial SpA had IBD at baseline (past or present); 15% (5 
of 34) and 10% (3 of 30) of these patients, respectively, or 13% (8 
of 64) overall experienced a flare during the adalimumab studies.
During the placebo-controlled periods, which ranged from 
5 to 80 weeks (most commonly 12 or 24 weeks), 3 IBD events 
(0.1/100 patient-years) in 3 patients were reported with adali-
mumab (among 6,781 patients; 2,752 patient-years of exposure) 
and 1 event (0.1/100 patient-years) with placebo (among 3,493 
patients; 1,246 patient-years of exposure) (Figure 2). All these 
events were reported in patients with axial SpA, corresponding 
to 0.5/100 patient-years (nonradiographic axial SpA, 2 events in 
2 patients; AS, n = 1) with adalimumab and 0.6/100 patient-years 
(nonradiographic axial SpA, n = 1) with placebo. No IBD events 
were reported in pediatric trials or in adult trials of RA, psoriasis, 
PsA, peripheral SpA, uveitis, and hidradenitis suppurativa during 
the placebo-controlled periods (Figure 2).
The rate of IBD events occurring over 1 year of adalimumab 
exposure across all trials was 0.1 (95% CI 0.1–0.2)/100 patient-
years. The 1-year rate of IBD events was 0.5 (95% CI 0.2–
0.9)/100 patient-years for the overall SpA group and 0.6 (95% CI 
0.3–1.2)/100 patient-years for patients with axial SpA (0.5 [95% CI 
0.1–0.6]/100 patient-years for AS, and 0.7 [95% CI 0.2–1.5]/100 
patient-years for nonradiographic axial SpA). The 1-year rate of 
IBD events was <0.1 (95% CI 0.0–0.1)/100 patient-years in RA 
and 0.0 (95% CI 0.0–0.2)/100 patient-years in adult psoriasis trials 
(1 IBD event). No IBD events were reported during the 1-year 
period in all the other adult populations (i.e., PsA, uveitis, hidrad-
enitis suppurativa), as well as in pediatric psoriasis and all JIA 
 (polyarticular JIA and pediatric ERA).
The majority of the 41 IBD events reported across trials were 
not serious events; only 9 serious IBD AEs were observed (5 flares 
and 4 new-onset events), none of which were life threatening or 
led to death. Of these, 4 events were observed in RA trials, 3 
events in AS trials, 1 event in the peripheral SpA trial, and 1 event 
in a hidradenitis suppurativa trial.
DISCUSSION
This analysis of 75 adalimumab clinical trials in >24,000 adult 
and pediatric patients and 36,508 cumulative patient-years of 
exposure to adalimumab demonstrated that the rates of IBD AEs 
were generally low in adalimumab-exposed patients across dis-
eases and comparable to the rates observed in placebo-treated 
patients. Furthermore, all events occurred in adult patients, and 
no IBD events were noted in adult patients with PsA or uveitis.
IMIDs are a broad group of diseases that share common 
inflammatory pathways, and multiple IMIDs commonly may coex-
ist within a patient (1,7,9,10). IBD is a relatively common extraar-
ticular manifestation in certain IMIDs, such as the SpA family of 
diseases. For AS and nonradiographic axial SpA specifically, 
5–10% of patients are estimated to be affected by overt IBD, with 
subclinical disease observed in up to 60% of patients (7,8). In our 
analyses, the rate of IBD-related AEs (both flares and new-onset 
events) in patients with axial SpA (nonradiographic axial SpA and 
AS) was low, with 18 events reported in 2,889 patients, repre-
senting 2,975 patient-years of exposure to adalimumab (0.6/100 
patient-years [95% CI 0.4–1.0]). Furthermore, the rates of IBD AEs 
in patients with axial SpA were similar for adalimumab and placebo 
groups during the placebo-controlled periods (0.5/100 patient-
years versus 0.6/100 patient-years). The incidence of IBD AEs 
was numerically slightly higher in AS than nonradiographic axial 
SpA, 0.7/100 patient-years versus 0.5/100 patient-years, respec-
tively, but the confidence intervals were overlapping (Figure 1).
In an earlier meta-analysis of TNF inhibitor clinical trials, the 
pooled incidence rate of new onset/worsening of IBD in placebo- 
treated patients with AS was 1.3/100 patient-years (95% CI 0.2–
4.8; 150 patient-years), while in patients treated with TNF inhibi-
tors infliximab, etanercept, or adalimumab, the rates, respectively, 
were 0.2/100 patient-years (95% CI 0–0.9; 618 patient-years), 
2.2/100 patient-years (95% CI 1.2–3.8; 625 patient-years), and 
2.3/100 patient-years (95% CI 0.5–6.6; 132 patient-years) (11). 
Based on data from 2,026 patients representing 2,120 patient-
years of adalimumab exposure, the rate of IBD in patients with 
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AS observed in the present analysis (0.7/100 patient-years [95% 
CI 0.4–1.1]) was lower than in that earlier analysis, which included 
only 1 randomized clinical trial (that was also included here) and 1 
small open-label study.
No newer data comparing the incidence of IBD AEs in patients 
with axial SpA receiving nonbiologic versus biologic therapy have 
been published. In the Be-Giant cohort of patients with axial SpA 
fulfilling the Assessment of SpondyloArthritis international Society 
classification criteria (12), the combined incidence rate of flares and 
new onset IBD was 1.64/100 patient-years (95% CI 0.74–3.11) 
for nonbiologic versus 2.73/100 patient-years (95% CI 1.00–5.95) 
for biologic therapy (A. De Craemer and D. Elewaut personal 
communication). These incidence rates are much higher than in our 
analysis of adalimumab axial SpA trials. Similarly, the percentage 
of patients who experienced at least 1 IBD flare was higher in the 
Be-Giant cohort versus the pooled adalimumab axial SpA trial pop-
ulation (33% versus 13%), although baseline IBD prevalence was 
similar (6% versus 5%). However, drawing conclusions based on 
this comparison is difficult, because the total number of axial SpA 
patients included in the Be-Giant cohort to date is relatively low, and 
the total follow-up duration is relatively short (269 patients with a 
total of 769 patient-years follow-up). Furthermore, channeling bias 
cannot be ruled out because patients with more active/severe IBD 
could be preferentially started on biologic therapy in general practice.
Figure 2. Patients from placebo-controlled period of adalimumab clinical trials across diseases. Excludes adalimumab trials in Crohn’s 
disease, ulcerative colitis, and Behçet’s disease. A, Rates of all inflammatory bowel disease (IBD) events as incidence per 100 patient-years 
(PY). B, First IBD events only per 100 patient-years (with patients censored after first event). Duration of placebo periods were 5 weeks 
(1 study), 12 weeks (13 studies), 16 weeks (4 studies), 24 weeks (10 studies), 26 weeks (1 study), 32 weeks (1 study), 40 weeks (1 study), 
52 weeks (1 study), and up to 80 weeks (2 studies). 95% CI = 95% confidence interval; * = includes patients with psoriatic arthritis (PsA), 
non-PsA peripheral spondyloarthritis (pSpA), nonradiographic axial SpA (nr-axSpA), and ankylosing spondylitis (AS) from interventional 
adalimumab trials; † = includes patients with nonradiographic axial SpA and AS from interventional adalimumab trials; ‡ = includes patients 
with polyarticular juvenile idiopathic arthritis (JIA) and pediatric enthesitis-related arthritis from interventional adalimumab trials; HS = hidradenitis 
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Patients with PsA and psoriasis, who share similar inflam-
matory disease pathways with the greater SpA family, are also at 
increased risk of concomitant IBD (9,10). Up to 33% of patients 
with PsA may have bowel involvement (overt or subclinical) (9), 
and the incidence rate (unspecified whether new onset or flare) 
in patients with psoriasis and PsA of Crohn’s disease (0.032 and 
0.057 per 100 patient-years, respectively) and ulcerative colitis 
(0.079 and 0.11 per 100 patient-years, respectively) was higher 
compared with the general population (Crohn’s disease 0.017/100 
patient-years; ulcerative colitis 0.045/100 patient-years) (10). In 
our analysis, no IBD cases were observed among patients with 
PsA, and only 1 event (0.0/100 patient-years) was observed in 
adult patients with psoriasis.
Because IL-17 inhibition is a therapeutic option for patients 
with psoriasis, PsA, and AS (patients who are at increased risk 
of IBD as a manifestation of their disease), it is relevant to dis-
cuss findings for drugs with this mechanism of action. Clinical trial 
data for the IL-17 inhibitor secukinumab suggest no benefit and 
possible worsening of Crohn’s disease (5). The potential risk of 
Crohn’s disease and ulcerative colitis events after secukinumab 
exposure was demonstrated in real-world databases (13), and 
product labeling recommends caution when treating patients with 
AS, PsA, or psoriasis who also have IBD due to risk of IBD exac-
erbation (6). A recent pooled analysis of 10 secukinumab studies 
across these 3 indications reported Crohn’s disease and ulcera-
tive colitis incidence rates for patients with psoriasis (n = 3,430) 
of 0.11/100 patient-years (3 events total; 3 flares) and 0.15/100 
patient-years (4 events total; 2 flares), respectively; for patients 
with PsA (n = 974), 0.07/100 patient-years (1 event total; 0 flares) 
and 0.14/100 patient-years (2 events total; 1 flare), respectively; 
and for patients with AS (n = 591), 0.77/100 patient-years (8 
events total; 3 flares) and 0.29/100 patient-years (3 events total; 1 
flare), respectively. Patients with active IBD were excluded from the 
studies (14). An additional pooled analysis of data from the subset 
of 3 MEASURE trials in 794 patients (1,706 patient-years) with 
AS receiving secukinumab for up to 3 years found an IBD rate of 
0.7/100 patient-years (15). However, these reports did not specify 
the severity of IBD AEs in the secukinumab trials. In our analysis, 
only 9 of 41 IBD AEs across 75 adalimumab trials were serious; 
3 occurred in patients with AS, and none in patients with nonra-
diographic axial SpA. Further, none of the 15 axial SpA patients 
who experienced IBD AEs prematurely discontinued from the trial. 
Risks of new onset or worsening of IBD are largely unknown for 
other biologic therapies that may work along the IBD pathway.
The strengths of this analysis include the fact that IBD data 
were obtained from a large, well-characterized clinical trial data-
base and included a comparison versus placebo, although place-
bo-controlled periods were limited. The limitations of our analysis 
include lack of systematic identification of concomitant IBD at 
baseline in diseases other than axial SpA to distinguish new IBD 
onsets from IBD flares. AE reporting was the mechanism used to 
identify IBD events, and AEs were not systematically confirmed by 
additional diagnostic procedures. This analysis also did not include 
nonspecific terms that may be related to IBD (such as diarrhea, 
blood in stool, etc.) because doing so would overestimate the true 
IBD incidence. It would be useful to know whether subclinical gut 
inflammation, common in patients with SpA, existed at baseline 
in patients with new-onset IBD occurring during the trials, but this 
information was not collected.
In conclusion, the rates of IBD AEs in adalimumab trials 
were generally low across diseases. In patients with axial SpA, 
who are known to be at an increased risk of IBD, the rates of IBD 
events were comparable between adalimumab- and placebo- 
treated patients, as well as with published pooled placebo rates 
across multiple AS clinical trials with TNF inhibitors. Based on the 
observed low rates of IBD and its approved indications for Crohn’s 
disease and ulcerative colitis, adalimumab is a reasonable thera-
peutic option for patients who are eligible for a biologic therapy 
and who are at risk for development or worsening of IBD. This 
analysis provides a benchmark for IBD AEs that other therapies, 
now and in the future, might be compared against.
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